Lilly Beats And Raises

Eli Lilly beat profit estimates and raised guidance. Pfizer did the same yesterday but the stock fell flat. I believe Eli Lilly has a better chance of rallying even though it has already had a nice run, as it is the most hated pharmaceutical stock. Goldman Sachs has it on its Conviction Sell List. When a stock is hated and does well, there is a lot of upside potential. Eli Lilly is my second largest holding, next to Pfizer.

2 comments:

Anonymous said...

LLY beats expectations, yet is down 40 cents... gotta love it.

Anonymous said...

Gilead beat expectations and is down 3.6%. Apparently investors are concerned about patent expirations that take place from 2017 to 2021. Somehow the distant future doesn't worry anyone where Wells Fargo or Apple are concerned.